# PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

> **NCT05246670** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 88 (actual)

## Conditions studied

- Chemotherapy-Induced Peripheral Neuropathy
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **DRUG:** Palmidrol
- **DRUG:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT05246670
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-16
- **Primary completion:** 2024-02-12
- **Final completion:** 2026-02-28
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05246670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05246670, "PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05246670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*